Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| ID | DOID:0080909 |
| Name | castration-resistant prostate carcinoma |
| Definition | A prostate carcinoma that is characterized by continued growth and spread despite the surgical removal of the testes or medical intervention to block androgen production. |
| Source | DiseaseOntology.org |
| Alt Ids | |
| Path | disease disease of cellular proliferation cancer organ system cancer reproductive organ cancer male reproductive organ cancer prostate cancer prostate carcinoma castration-resistant prostate carcinoma |
| Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
|---|---|---|---|---|
| PTEN loss | Abiraterone + Ipatasertib | castration-resistant prostate carcinoma | sensitive | detail... |
| PTEN loss | Enzalutamide + GSK2636771 | castration-resistant prostate carcinoma | no benefit | detail... |
| PTEN inact mut | CC-115 + Enzalutamide | castration-resistant prostate carcinoma | predicted - sensitive | detail... |
| PIK3CA act mut | CC-115 + Enzalutamide | castration-resistant prostate carcinoma | predicted - sensitive | detail... |
| PTEN N323fs | Everolimus | castration-resistant prostate carcinoma | predicted - sensitive | detail... |
| TSC2 inact mut | CC-115 + Enzalutamide | castration-resistant prostate carcinoma | predicted - sensitive | detail... |
| TSC1 inact mut | CC-115 + Enzalutamide | castration-resistant prostate carcinoma | predicted - sensitive | detail... |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03436485 | Phase Ib/II | ODM-208 | Safety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-resistant Prostate Cancer (CYPIDES) | Active, not recruiting | USA | GBR | FRA | FIN | 0 |
| NCT03903835 | Phase III | Docetaxel Cabazitaxel Carboplatin Abiraterone Enzalutamide | ProBio: A Biomarker Driven Study in Patients With Metastatic Castrate Resistant Prostate Cancer (ProBio) | Recruiting | SWE | NOR | CHE | BEL | 0 |
| NCT04104776 | Phase Ib/II | Enzalutamide + Tulmimetostat Tulmimetostat | A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas | Recruiting | USA | POL | ITA | GBR | FRA | ESP | 1 |
| NCT04221542 | Phase I | AMG 509 Abiraterone + AMG 509 AMG 509 + Enzalutamide | Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer | Recruiting | USA | ESP | DEU | CHE | AUS | 5 |
| NCT04434482 | Phase I | Senaparib + Temozolomide | IMP4297 in Combination With Temozolomide in Patients With Advanced Solid Tumors and Small Cell Lung Cancer | Completed | USA | AUS | 3 |
| NCT04557449 | Phase I | Letrozole + PF-07220060 Fulvestrant + PF-07220060 Enzalutamide + PF-07220060 PF-07220060 Midazolam + PF-07220060 | Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors (CDK4i) | Active, not recruiting | USA | SVK | GBR | CZE | ARG | 3 |
| NCT04606446 | Phase I | PF-07248144 PF-07248144 + Vepdegestrant Fulvestrant + PF-07220060 + PF-07248144 Fulvestrant + Palbociclib + PF-07248144 Fulvestrant + PF-07248144 Letrozole + Palbociclib + PF-07248144 | Study of PF-07248144 in Advanced or Metastatic Solid Tumors (KAT6) | Recruiting | USA | AUS | 3 |
| NCT04644770 | Phase I | JNJ-69086420 | A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer | Recruiting | USA | 0 |
| NCT04717154 | Phase II | Ipilimumab + Nivolumab | Ipilimumab With Nivolumab for Molecular-selected Patients With Castration-resistant Prostate Cancer (INSPIRE) | Active, not recruiting | NLD | 0 |
| NCT04839991 | Phase I | CB307 | Study of CB307 in Patients With Advanced and/or Metastatic PSMA-positive Tumours. (POTENTIA) | Unknown status | USA | NLD | GBR | ESP | 0 |
| NCT04876651 | Phase III | Docetaxel Enzalutamide 177Lu-J591 + Abiraterone + Prednisolone Abiraterone + Prednisone 177Lu-J591 + Abiraterone + Prednisone 177Lu-J591 + Enzalutamide Abiraterone + Prednisolone 177Lu-J591 + Docetaxel | The Present Study Aims to Compare Patients Who Receive the Investigational Product (177Lu-DOTA-rosopatamab) Plus Standard of Care, in Comparison to Standard of Care Only | Recruiting | NZL | AUS | 0 |
| NCT04896697 | Phase Ib/II | XTX101 Pembrolizumab + XTX101 | XTX101 Monotherapy and XTX101 and Pembrolizumab Combination Therapy in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
| NCT04926181 | Phase II | Apalutamide + Cetrelimab | Apalutamide Plus Cetrelimab in Patients With Treatment-Emergent Small Cell Neuroendocrine Prostate Cancer | Terminated | USA | 0 |
| NCT04946370 | Phase Ib/II | Pembrolizumab 225Ac-J591 + Pembrolizumab | Maximizing Responses to Anti-PD1 Immunotherapy With PSMA-targeted Alpha Therapy in mCRPC | Recruiting | USA | 0 |
| NCT05005728 | Phase II | Cabazitaxel + XmAb20717 Docetaxel + XmAb20717 XmAb20717 Olaparib + XmAb20717 Cabazitaxel + Carboplatin + XmAb20717 | XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer | Completed | USA | 0 |
| NCT05057013 | Phase Ib/II | HMBD-001 | A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours | Active, not recruiting | GBR | 0 |
| NCT05107674 | Phase I | NX-1607 | A Study of NX-1607 in Adults With Advanced Malignancies | Recruiting | USA | GBR | 0 |
| NCT05159518 | Phase I | PRT2527 | A Study of PRT2527 in Participants With Advanced Solid Tumors | Completed | USA | 0 |
| NCT05219500 | Phase II | FPI-2265 | Targeted Alpha Therapy With 225Actinium-Prostate Specific Membrane Antigen (PSMA)-I&T of Castration-resISTant Prostate Cancer (TATCIST). (TATCIST) | Active, not recruiting | USA | 0 |
| NCT05241613 | Phase I | AC176 | A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer | Terminated | USA | 0 |
| NCT05256381 | Phase II | Pembrolizumab + SOT101 | A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors | Terminated | USA | POL | ITA | HUN | FRA | ESP | CZE | BEL | 1 |
| NCT05272709 | Phase Ib/II | Darolutamide + TT-702 TT-702 | TT-702 in Patients With Advanced Solid Tumours. (CURATE) | Recruiting | GBR | 0 |
| NCT05369000 | Phase Ib/II | LAVA-1207 | Trial of LAVA-1207 in Patients With Therapy Refractory Metastatic Castration Resistant Prostate Cancer | Terminated | USA | NLD | ESP | 0 |
| NCT05417594 | Phase Ib/II | AZD9574 + Trastuzumab deruxtecan AZD9574 + Datopotamab deruxtecan AZD9574 AZD9574 + Temozolomide | Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies (CERTIS1) | Recruiting | USA | SWE | GBR | ESP | DEU | AUS | 1 |
| NCT05434234 | Phase I | YL201 Atezolizumab + YL201 | A Study of YL201 in Patients With Advanced Solid Tumors | Recruiting | USA | POL | FRA | ESP | CAN | 1 |
| NCT05438329 | Phase Ib/II | DB-1305 BNT327 + DB-1305 DB-1305 + Pembrolizumab | First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors | Recruiting | USA | 2 |
| NCT05488548 | Phase I | NEO2734 | Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors | Recruiting | USA | 0 |
| NCT05501548 | Phase II | Olaparib | Phase II Study of PARP Inhibitor Olaparib and IV Ascorbate in Castration Resistant Prostate Cancer | Terminated | USA | 0 |
| NCT05534646 | Phase II | Apalutamide Apalutamide + Carotuximab | Study of Apalutamide With Carotuximab in Metastatic, Castration-Resistant Prostate Cancer | Recruiting | USA | 0 |
| NCT05592626 | Phase Ib/II | Invikafusp alfa | A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors (START-001) | Recruiting | USA | FRA | ESP | CAN | 0 |
| NCT05655715 | Phase II | Ipilimumab + Nivolumab | Checkpoint Inhibitors and SBRT for mCRPC (CheckPRO) | Completed | DNK | 0 |
| NCT05662397 | Phase Ib/II | HST-1011 Cemiplimab + HST-1011 | A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody | Active, not recruiting | USA | ESP | CAN | 0 |
| NCT05689021 | Phase II | Niraparib and abiraterone acetate + Prednisone | CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate Cancer and SPOP Gene Mutations | Recruiting | USA | 0 |
| NCT05700669 | Phase Ib/II | AsiDNA + Olaparib | Study To Assess Safety And Efficacy Of AsiDNA In Combination With Olaparib In Participants With Recurrent Solid Tumors | Completed | USA | 0 |
| NCT05720130 | Phase Ib/II | 212Pb-ADVC001 | Phase Ib/IIa Dose Escalation and Expansion Study of [²¹²Pb]Pb-ADVC001 in Metastatic Castration Resistant Prostate Cancer (TheraPb - Phase I/II Study). | Recruiting | AUS | 0 |
| NCT05730712 | Phase II | Enzalutamide + Pertuzumab/trastuzumab/hyaluronidase-zzxf | Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer, TraPPer Study | Active, not recruiting | USA | 0 |
| NCT05743621 | Phase I | Enzalutamide + TVB-2640 | Study of TVB-2640 in Men With Metastatic Castration-Resistant Prostate Cancer | Recruiting | USA | 0 |
| NCT05762536 | Phase II | Docetaxel Cabazitaxel + Darolutamide Darolutamide + Docetaxel Cabazitaxel | Docetaxel or Cabazitaxel With or Without Darolutamide in mCRPC (DAROTAXEL) | Recruiting | NLD | 0 |
| NCT05785741 | Phase Ib/II | DB-1310 | A Phase 1/2a Study of DB-1310 in Advanced/Metastatic Solid Tumors | Recruiting | USA | 1 |
| NCT05818683 | Phase I | Cetrelimab + Pasritamig | A Study of JNJ-78278343 in Combination With JNJ-63723283 (Cetrelimab) for Metastatic Castration-Resistant Prostate Cancer | Recruiting | USA | ESP | AUS | 0 |
| NCT05841563 | Phase I | PM54 | Clinical Trial of PM54 in Advanced Solid Tumors Patients. | Recruiting | USA | ESP | BEL | 0 |
| NCT05914116 | Phase Ib/II | DB-1311 + Enzalutamide Abiraterone + DB-1311 DB-1311 | A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors | Recruiting | USA | AUS | 2 |
| NCT05917470 | Phase Ib/II | ONCT-534 | A Clinical Study of ONCT-534 in Subjects With Metastatic Castration-resistant Prostate Cancer. | Terminated | USA | GBR | 0 |
| NCT05919264 | Phase Ib/II | Bevacizumab + Fluorouracil + FOG-001 + Leucovorin + Oxaliplatin FOG-001 + Nivolumab FOG-001 Bevacizumab + FOG-001 + Trifluridine-tipiracil hydrochloride | FOG-001 in Locally Advanced or Metastatic Solid Tumors | Recruiting | USA | 0 |
| NCT05932862 | Phase I | ISM3091 + Olaparib ISM3091 | A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors | Recruiting | USA | 0 |
| NCT05944237 | Phase Ib/II | Atezolizumab + HTL0039732 HTL0039732 | HTL0039732 in Participants With Advanced Solid Tumours | Recruiting | GBR | 0 |
| NCT05983198 | Phase Ib/II | 225Ac-PSMA-R2 | Phase I/II Study of [225Ac]Ac-PSMA-R2 in PSMA-positive Prostate Cancer, With/Without Prior 177Lu-PSMA RLT (SatisfACtion) | Recruiting | USA | FRA | CAN | AUS | 0 |
| NCT05997615 | Phase I | AMX-500 AMX-500 + Darolutamide AMX-500 + Enzalutamide | Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer | Recruiting | GBR | ESP | AUS | 0 |
| NCT05999968 | Phase I | Abemaciclib + Darolutamide | Abemaciclib Plus Darolutamide in Prostate Cancer That Has Spread After Initial Treatment | Active, not recruiting | USA | ESP | DEU | 0 |
| NCT06039371 | Phase II | Etoposide + Testosterone cypionate Carboplatin + Testosterone cypionate | Supraphysiological Androgen to Enhance Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study | Recruiting | USA | 0 |
| NCT06052306 | Phase I | BAY3546828 | A Study to Learn How Safe the Study Treatment Actinium-225-macropa-pelgifatamab (BAY3546828) is, How it Affects the Body, How it Moves Into, Through and Out of the Body, and About Its Anticancer Activity in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC) | Recruiting | USA | SWE | NLD | ITA | GBR | FIN | CHE | CAN | 0 |
| NCT06126731 | Phase Ib/II | Amoxicillin + Enzalutamide + Metronidazole Ciprofloxacin + Enzalutamide + Vancomycin | Combination Study of Antibiotics With Enzalutamide (PROMIZE) | Recruiting | GBR | CHE | 0 |
| NCT06134232 | Phase II | Sipuleucel-T | Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE + One Infusion of Sipuleucel-T (ProvONE) | Recruiting | USA | 0 |
| NCT06136624 | Phase III | Dexamethasone + Fludrocortisone + ODM-208 Enzalutamide Abiraterone + Prednisone | Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003) (OMAHA-003) | Recruiting | USA | TUR | SWE | POL | NZL | NOR | NLD | ITA | ISR | IRL | HUN | GBR | FRA | FIN | ESP | DNK | DEU | CZE | CAN | BRA | AUT | AUS | ARG | 13 |
| NCT06136650 | Phase III | Abiraterone + Prednisone Dexamethasone + Fludrocortisone + ODM-208 Enzalutamide | A Study of MK-5684 Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004) | Recruiting | USA | TUR | SWE | SVK | ROU | NZL | LVA | LTU | ITA | ISR | IRL | HUN | GRC | GBR | FRA | EST | ESP | DEU | CZE | CAN | BRA | AUS | 17 |
| NCT06136884 | Phase I | AO-252 | A First-In-Human, Phase 1 Study Evaluating Oral TACC3 PPI Inhibitor, AO-252, in Advanced Solid Tumors With or Without Brain Metastases | Recruiting | USA | 0 |
| NCT06172478 | Phase II | Patritumab deruxtecan | A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors | Recruiting | USA | NOR | NLD | ITA | HUN | GBR | FRA | ESP | CAN | BEL | AUS | 3 |
| NCT06190899 | Phase Ib/II | Darolutamide + Gedatolisib | Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer | Recruiting | USA | GBR | FRA | ESP | 0 |
| NCT06193486 | Phase I | MSGV1-PSCA-8T28Z Cyclophosphamide + Fludarabine | Autologous Gamma Delta T Cells to Target Prostate Stem Cell Antigen in mCRPC | Recruiting | USA | 0 |
| NCT06200103 | FDA approved | lutetium Lu 177 vipivotide tetraxetan | Schedule De-Escalation of 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer | Recruiting | USA | 0 |
| NCT06216249 | Phase II | lutetium Lu 177 vipivotide tetraxetan | Evaluation of a Flexible Dosing Schedule of 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer | Recruiting | USA | 0 |
| NCT06217822 | Phase I | BAY3563254 | First-in-human Study of 225Ac-PSMA-Trillium (BAY 3563254) in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC) (PAnTHA) | Recruiting | USA | SWE | NLD | ITA | GBR | FIN | CHE | CAN | BEL | 0 |
| NCT06228053 | Phase II | Enzalutamide + SX-682 | Study of SX-682 Plus Enzalutamide in Men With Abiraterone-Resistant Metastatic Castration Resistant Prostate Cancer (SYNERGY-201) | Recruiting | USA | 0 |
| NCT06242470 | Phase I | MGC026 | A Study of MGC026 in Participants With Advanced Solid Tumors | Recruiting | USA | GBR | AUS | 0 |
| NCT06253130 | Phase Ib/II | IMP1734 | A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors | Recruiting | USA | FRA | ESP | DNK | CAN | AUS | 2 |
| NCT06305598 | Phase I | Leuprolide + Testosterone cypionate | Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer | Recruiting | USA | 0 |
| NCT06334432 | Phase Ib/II | NUV-1511 | Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
| NCT06401980 | Phase II | Docetaxel Radium Ra 223 dichloride 177Lu-rhPSMA-10.1 Darolutamide Olaparib Cabazitaxel | Darolutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Recruiting | CHE | 0 |
| NCT06421935 | Phase I | HRS-1167 + M1774 HRS-1167 Abiraterone + HRS-1167 + Prednisone | M9466 Alone or in Combination in Advanced Solid Tumors (DDriver 501) | Recruiting | USA | ESP | AUS | 2 |
| NCT06480110 | Phase Ib/II | Docetaxel Docetaxel + Ebastine | Ebastine in Combination With Docetaxel as a Treatment for Castration-resistant Metastatic Prostate Cancer | Recruiting | DNK | 0 |
| NCT06492122 | Phase I | [225]Ac-FL-020 | Study With [225Ac]Ac-FL-020 in mCRPC Participants (ProTACT) | Recruiting | USA | TUR | AUS | 0 |
| NCT06531499 | Phase I | lutetium Lu 177 vipivotide tetraxetan | A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults With Metastatic Castration-resistant Prostate Cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) Study (RADIODOSE) | Recruiting | USA | NLD | GBR | ESP | DEU | CHE | 0 |
| NCT06549465 | Phase II | 225Ac-J591 | Study Evaluating Dosimetry, Randomized Dose Optimization, Dose Escalation and Efficacy of Ac-225 Rosopatamab Tetraxetan in Participants With PSMA PET-Positive Castration-Resistant Prostate Cancer | Recruiting | USA | 0 |
| NCT06551324 | Phase III | Enzalutamide + PF-06821497 Enzalutamide Docetaxel | A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1). (MEVPRO-1) | Recruiting | USA | TUR | SWE | SVK | POL | NLD | ITA | HUN | GRC | GBR | FRA | ESP | DEU | CZE | CAN | BRA | AUS | ARG | 5 |
| NCT06560632 | Phase I | Olaparib + RP-3467 RP-3467 | Phase 1 Trial of RP-3467 Alone and in Combination With Olaparib in Participants With Advanced Solid Tumors (POLAR) | Active, not recruiting | USA | 0 |
| NCT06576037 | Phase I | CBP-1019 + Enzalutamide CBP-1019 + Pembrolizumab Bevacizumab + CBP-1019 + Fluorouracil + Leucovorin + Oxaliplatin CBP-1019 + Fluorouracil + Leucovorin + Oxaliplatin | Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin | Recruiting | USA | 0 |
| NCT06582628 | Phase II | Enzalutamide Enzalutamide + Talazoparib | Talazoparib Plus Enzalutamide After Progression to Abiraterone in Metastatic Prostate Cancer: (TEAM PC) (TEAM PC) | Recruiting | ESP | 0 |
| NCT06592924 | Phase III | Enzalutamide Abiraterone Darolutamide Abiraterone + Docetaxel Apalutamide + Docetaxel Docetaxel + Enzalutamide Apalutamide Darolutamide + Docetaxel | Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response (TRIPLE-SWITCH) | Recruiting | USA | CAN | 0 |
| NCT06609005 | Phase I | Dexamethasone + Fludrocortisone + INV-9956 | A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of INV-9956 in Adult Patients With Advanced Metastatic Castration Resistant Prostate Cancer | Recruiting | USA | 1 |
| NCT06610825 | Phase II | Trastuzumab deruxtecan | Castrate Resistant Prostate Cancer Enhertu Therapy (CaRPET) | Recruiting | USA | 0 |
| NCT06616155 | Phase Ib/II | Enzalutamide + Ruxolitinib | Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer | Recruiting | USA | 0 |
| NCT06634849 | Phase Ib/II | PTT-4256 | An Open Label Dose Finding Study of PTT-4256 in Patients With Solid Tumours. | Recruiting | AUS | 0 |
| NCT06705686 | Phase I | (R)-9bMS | Novel ACK1 Inhibitor (R)-9b in Patients with Prostate Cancer (PHAROS) | Not yet recruiting | USA | 0 |
| NCT06725758 | Phase Ib/II | ODM-212 | Two-part, First-in-Human Study on ODM-212 in Subjects with Selected Advanced Solid Tumours (TEADES) | Recruiting | GBR | 0 |
| NCT06782555 | Phase Ib/II | Balstilimab + Evofosfamide + Zalifrelimab | A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab | Recruiting | USA | 0 |
| NCT06784193 | Phase I | Fulvestrant + OP-3136 OP-3136 + Palazestrant OP-3136 | Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors | Recruiting | USA | AUS | 0 |
| NCT06830850 | Phase I | HRS-5041 | A Trial of HRS-5041-103 to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-5041 in Subjects With Metastatic Castration-resistant Prostate Cancer | Recruiting | AUS | 0 |
| NCT06842498 | Phase II | FOR46 | A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Recruiting | USA | 0 |
| NCT06844383 | Phase II | Enzalutamide + Talazoparib Talazoparib | A Study of Talazoparib with or Without Enzalutamide in People with Prostate Cancer Who Have Previously Received Abiraterone Acetate (TALENT) | Recruiting | USA | 0 |
| NCT06866938 | Phase II | lutetium Lu 177 vipivotide tetraxetan | Study of Re-treatment With [177Lu]Lu-PSMA in Men With Metastatic Castration Resistance Prostate Cancer (ReaLuP) | Recruiting | FRA | 0 |
| NCT06894511 | Phase II | Enzalutamide + lutetium Lu 177 vipivotide tetraxetan lutetium Lu 177 vipivotide tetraxetan Abiraterone + lutetium Lu 177 vipivotide tetraxetan | An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPC (PSMAndARPI) | Recruiting | USA | 0 |
| NCT06907043 | Phase Ib/II | EIK1004 | A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors. (EIK1004-001) | Recruiting | USA | AUS | 1 |
| NCT06909825 | Phase II | FPI-2265 + Olaparib | FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Active, not recruiting | AUS | 0 |
| NCT06925737 | Phase III | Docetaxel + Prednisone Ifinatamab deruxtecan | A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001) | Recruiting | USA | SWE | POL | NOR | NLD | ITA | ISR | IRL | GRC | FRA | ESP | DNK | DEU | CZE | CHE | BRA | AUT | AUS | ARG | 12 |
| NCT06943495 | Phase I | lutetium Lu 177 vipivotide tetraxetan | Personalized vs. Fixed-Activity 177Lu-PSMA-617 Radiopharmaceutical Therapy (PRODIGY-2) (PRODIGY-2) | Recruiting | CAN | 0 |
| NCT06959706 | Phase I | TGW101 + TRG001 | Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TGW101 in Participants With Advanced Solid Tumors | Recruiting | USA | 0 |
| NCT06966024 | Phase I | DCC-2812 | Study of DCC-2812 in Participants With Advanced Genitourinary Cancers | Recruiting | USA | 0 |
| NCT06990880 | Phase Ib/II | GSK5458514 | A Study of GSK5458514 Administered Alone or In Combination With Other Anti-Cancer Agents in Participants With Prostate Cancer | Recruiting | USA | CAN | 1 |
| NCT06999187 | Phase I | DR-0202 | A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas | Recruiting | USA | 0 |
| NCT07002320 | Phase Ib/II | Apalutamide + SX-682 | Investigating SX-682 in Combination With Apalutamide in Metastatic Castration-resistant Prostate Cancer (ASpiRE) | Recruiting | GBR | CHE | 0 |
| NCT07025512 | Phase II | lutetium Lu 177 vipivotide tetraxetan | 177Lu-PSMA-617 in Metastatic Castration Resistant Prostate Cancer (mCRPC) With Bone Marrow Involvement and Cytopenia | Recruiting | USA | 0 |
| NCT07047118 | Phase II | ARV-766 + lutetium Lu 177 vipivotide tetraxetan lutetium Lu 177 vipivotide tetraxetan | A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) | Recruiting | USA | NLD | ITA | ISR | FRA | ESP | DEU | CZE | CAN | AUT | AUS | 3 |
| NCT07082920 | Phase I | ARX517 + Pasritamig | A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer | Recruiting | USA | 0 |
| NCT07103018 | Phase I | KTX-2001 Darolutamide + KTX-2001 | A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001) (STRIKE-001) | Recruiting | USA | 0 |
| NCT07145177 | Phase I | lutetium Lu 177 vipivotide tetraxetan | 177Lu-PSMA-617 With Liver Directed Therapy in Metastatic Castration Resistant Prostate Cancer | Not yet recruiting | USA | 0 |
| NCT07145255 | Phase Ib/II | MBRC-201 | Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors | Recruiting | USA | 0 |
| NCT07164443 | Phase III | Pasritamig | A Study of Pasritamig Versus Placebo in Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC) (KLK2-comPAS) | Recruiting | USA | GBR | CAN | AUS | 3 |
| NCT07181161 | Phase Ib/II | AZD0516 + AZD9574 AZD0516 | Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer (SEACLIFF) | Recruiting | USA | POL | ITA | GBR | FRA | ESP | BRA | 3 |
| NCT07189403 | Phase I | DS9051b | A Study of DS9051b in Participants With Advanced or Metastatic Adrenocortical Carcinoma and Metastatic Castration-resistant Prostate Cancer | Recruiting | USA | GBR | FRA | 0 |
| NCT07192614 | Phase Ib/II | AZD6621 | A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer (ACTIVATED-4-PC) | Recruiting | USA | 3 |
| NCT07206056 | Phase Ib/II | ARV-766 + Tulmimetostat lutetium Lu 177 vipivotide tetraxetan | An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01) (TulmiSTAR-01) | Recruiting | USA | AUS | 2 |
| NCT07213674 | Phase III | Docetaxel Cabazitaxel Abiraterone Abiraterone + AMG 509 | A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer | Recruiting | USA | GBR | 0 |
| NCT07214961 | Phase I | AB001 | Study of Alpha Radioligand Therapy AB001 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) (ARTISAN) | Recruiting | USA | 0 |
| NCT07219147 | Phase I | lutetium Lu 177 vipivotide tetraxetan lutetium Lu 177 vipivotide tetraxetan + Sipuleucel-T | 177^Lu-PSMA-617 in Combination With Sipuleucel-T for the Treatment of Metastatic Castration-Resistant Prostate Cancer | Not yet recruiting | USA | 0 |
| NCT07226713 | Phase II | Pacritinib | Pacritinib in Participants With Metastatic Castrate-Resistant Prostate Cancer That Progressed on or After Prior Treatment With Androgen Receptor Signaling Inhibitors (POSTPONE) | Not yet recruiting | USA | 0 |
| NCT07226986 | Phase Ib/II | AMO959 + lutetium Lu 177 vipivotide tetraxetan Abiraterone + AMO959 + lutetium Lu 177 vipivotide tetraxetan AMO959 + Enzalutamide + lutetium Lu 177 vipivotide tetraxetan Abiraterone + lutetium Lu 177 vipivotide tetraxetan Enzalutamide + lutetium Lu 177 vipivotide tetraxetan | A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC | Recruiting | AUS | 0 |